111 Capital Decreases Stake in Pfizer Inc. $PFE

Key Points

• 111 Capital has reduced its stake in Pfizer Inc. by 41.7%, selling 28,807 shares, leaving the fund with 40,236 shares valued at approximately $975,000.
• Several institutional investors, including Pacer Advisors and Amundi, have significantly increased their positions in Pfizer, with Pacer Advisors' stake rising by 856.8%.
• Pfizer reported a 10.3% year-over-year revenue increase, achieving $14.65 billion in revenue for the last quarter and exceeding earnings estimates with $0.78 EPS.

111 Capital decreased its position in Pfizer Inc. (NYSE:PFE - Free Report) by 41.7% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 40,236 shares of the biopharmaceutical company's stock after selling 28,807 shares during the period. 111 Capital's holdings in Pfizer were worth $975,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PFE. Pacer Advisors Inc. increased its stake in Pfizer by 856.8% in the 1st quarter. Pacer Advisors Inc. now owns 20,053,828 shares of the biopharmaceutical company's stock valued at $508,164,000 after buying an additional 17,957,928 shares during the last quarter. Amundi grew its position in shares of Pfizer by 43.4% during the 1st quarter. Amundi now owns 52,090,403 shares of the biopharmaceutical company's stock valued at $1,265,277,000 after acquiring an additional 15,758,846 shares during the period. Nuveen LLC bought a new position in shares of Pfizer during the 1st quarter valued at approximately $389,861,000. Goldman Sachs Group Inc. grew its position in shares of Pfizer by 51.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 26,456,457 shares of the biopharmaceutical company's stock valued at $670,407,000 after acquiring an additional 9,041,990 shares during the period. Finally, Assenagon Asset Management S.A. grew its position in shares of Pfizer by 307.5% during the 1st quarter. Assenagon Asset Management S.A. now owns 10,046,340 shares of the biopharmaceutical company's stock valued at $254,574,000 after acquiring an additional 7,581,030 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Pfizer Stock Up 1.1%

PFE opened at $27.37 on Friday. The company has a 50 day moving average of $24.67 and a 200 day moving average of $24.14. The company has a market cap of $155.59 billion, a PE ratio of 14.56, a price-to-earnings-growth ratio of 0.88 and a beta of 0.55. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $30.43. The company has a current ratio of 1.16, a quick ratio of 0.85 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The company had revenue of $14.65 billion during the quarter, compared to the consensus estimate of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. During the same period last year, the firm earned $0.60 EPS. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

PFE has been the subject of a number of research reports. Morgan Stanley increased their target price on shares of Pfizer from $32.00 to $33.00 and gave the company an "equal weight" rating in a research report on Wednesday, August 6th. Weiss Ratings reissued a "hold (c-)" rating on shares of Pfizer in a research report on Saturday, September 27th. Citigroup increased their target price on shares of Pfizer from $25.00 to $26.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Bank of America increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the company a "neutral" rating in a research report on Friday. Finally, UBS Group reissued a "neutral" rating and set a $28.00 target price on shares of Pfizer in a research report on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, Pfizer presently has an average rating of "Hold" and a consensus price target of $28.41.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.